The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib by Molecular Docking Studies

E-ISSN： 1875-628x|4|6|422-425

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.4, Iss.6, 2007-09, pp. : 422-425

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors: Synthesis, Anti-inflammatory Activity and Molecular Docking Studies

Medicinal Chemistry, Vol. 13, Iss. 5, 2017-07 ,pp. : 484-497

Bentham Science Publishers

Access to resources Recommend Favorite

Lumiracoxib: new COX-2 inhibitor effective in osteoarthritis

Inpharma, Vol. 1, Iss. 1403, 2003-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Ester Prodrugs of Ketoprofen: Synthesis, In Vitro Stability, In Vivo Biological Evaluation and In Silico Comparative Docking Studies Against COX-1 and COX-2

Current Drug Discovery Technologies, Vol. 13, Iss. 1, 2016-03 ,pp. : 41-57

Bentham Science Publishers

Access to resources Recommend Favorite

COX-2 Selectivity and Inflammatory Processes.

Current Medicinal Chemistry, Vol. 7, Iss. 11, 2000-11 ,pp. : 1145-1161

Bentham Science Publishers

Access to resources Recommend Favorite

Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme

Current Medicinal Chemistry, Vol. 20, Iss. 35, 2013-11 ,pp. : 4350-4369

Bentham Science Publishers

Access to resources Recommend Favorite